Sep. 26 at 4:35 AM
$ASRT Trump's pharmaceutical tariffs......I think this makes it more likely for ASRT to be sold than to buy another product line. I say that because "U.S. manufactured drugs" will be selling for a premium now. There is a NASDAQ company, DMIIU, (and another sister company that debuted last Feb, DMAAU) that just IPO'd this week, its name is "drugs made in America incorporated". Both raised around
$500M in cash but even the shell company that IPO'd in Feb hasn't closed a deal yet. This tells you there will be competition (and premium) to get U.S. drugs. On the other hand, ASRT has Sympazan + Rolvedon + cash. Rolvedon will be hit with tariff but a company acquiring ASRT (if it is large enough) may be able to work the deal with Hamni Pharmaceuticals to manufacture drug in U.S for them. You get that one aspect done and ASRT becomes a nice take over target (after shareholder lawsuits are done) vs them having to compete to buy another product line. Imo, CEO is smart enough to think about it.
